--- title: "Genesco Reaches Analyst Target Price" type: "News" locale: "en" url: "https://longbridge.com/en/news/284602831.md" description: "Genesco Inc. (GCO) shares have surpassed the average analyst 12-month target price of $36.00, trading at $36.03. Analysts may react by downgrading or raising their target prices based on company performance. Current analyst targets range from $29.00 to $43.00, with a standard deviation of $6.582. Investors are encouraged to evaluate whether the stock's price is likely to rise further or if it has become overvalued. The average analyst rating for GCO remains at 2.2, indicating a generally favorable outlook." datetime: "2026-04-29T15:10:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284602831.md) - [en](https://longbridge.com/en/news/284602831.md) - [zh-HK](https://longbridge.com/zh-HK/news/284602831.md) --- # Genesco Reaches Analyst Target Price In recent trading, shares of Genesco Inc. (Symbol: GCO) have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 4 different analyst targets within the Zacks coverage universe contributing to that average for Genesco Inc., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $29.00. And then on the other side of the spectrum one analyst has a target as high as $43.00. The standard deviation is $6.582. But the whole reason to look at the _average_ GCO price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with GCO crossing above that average target price of $36.00/share, investors in GCO have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $36.00 just one stop on the way to an even _higher_ target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Genesco Inc.: **Recent GCO Analyst Ratings Breakdown** » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 2 2 2 2 Buy ratings: 0 0 0 0 Hold ratings: 3 3 3 3 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 _Average rating:_ _2.2_ _2.2_ _2.2_ _2.2_ The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on GCO — FREE. The Top 25 Broker Analyst Picks of the S&P 500 » ##### Also see: • Earnings History • SWKS 13F Filers • Railroads Dividend Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [GCO.US](https://longbridge.com/en/quote/GCO.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [SWKS.US](https://longbridge.com/en/quote/SWKS.US.md) ## Related News & Research - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md) - [This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/286923370.md) - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)